Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of FBPaldolase in preparation of AMPK activating drugs

A drug and application technology, applied in the direction of drug combination, application, microorganisms, etc., can solve the problems of inhibiting aldolase and the lack of universality of aldolase inhibition

Active Publication Date: 2018-05-29
XIAMEN VIVOHEALTHS TECH CO LTD
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In addition, the inventor's preliminary experimental results show that TDZD-8 cannot inhibit aldolase in MEF cells, which at least shows that the inhibition of aldolase by this inhibitor is not universal

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of FBPaldolase in preparation of AMPK activating drugs
  • Use of FBPaldolase in preparation of AMPK activating drugs

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0099] Embodiment 1: shRNA suppresses the expression of ALDOA-C gene

[0100] 1. Experimental materials and main reagents

[0101] Cell line: mouse fibroblast MEF, which is an immortalized MEF, that is, after the fibroblasts are isolated from mouse embryos, they are transfected with SV40 T antigen to make the cells immortal. For the construction method, please refer to the literature Lei Y, Methods MolBiol. 2013; 1031:59-64. Generation and culture of mouse embryonic fibroblasts.

[0102] Human embryonic kidney cells HEK293T (cat.CRL-3216) were purchased from ATCC.

[0103] Vector pLVX-IRES (cat. #631849) was purchased from Clontech.

[0104] Transfection reagent: Lipofectamine 2000 (cat.11668-027), purchased from Invitrogen.

[0105] Doxycycline (cat. S4163) was purchased from Selleckchem.

[0106] Dulbecco's modified Eagle's medium (DMEM, Gibco, cat. 11965) was purchased from Thermofisher.

[0107] Primary antibody used in Western:

[0108] anti-ALDOA (cat.#8060), pur...

Embodiment 2

[0142] Example 2: shRNA targeting ALDOA-C can activate AMPK

[0143] 1. Experimental materials and main reagents

[0144] Primary antibody used in Western:

[0145] Rabbit 548anti-phospho-AMPKα-T172 (cat#2535), purchased from Cell Signaling Technology;

[0146] anti-AMPKα (cat#2532, 1:1000 for IB), purchased from Cell Signaling Technology;

[0147] anti-phospho-ACC-Ser79 (cat.#3661, 1:1000 for IB), purchased from Cell Signaling Technology;

[0148] anti-ACC (cat.#3662, 1:1000 for IB), purchased from Cell Signaling Technology.

[0149] Other primary and secondary antibodies used are as described in Example 1.

[0150] DMEM without glucose (Gibco, cat. 11966) was purchased from Thermofisher.

[0151] 2. Experimental method

[0152] (1) First, with reference to the method described in Example 1, prepare the following figure 1 ALDOA-C knockdown MEF cells are shown. Among them, the shRNA targeting GFP (Green Fluorescent Protein Green Fluorescent Protein) is used as the co...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the field of biomedicine and relates to use of FBP aldolase in preparation of AMPK activating drugs. The present invention also relates to use of the FBP aldolase in preparation of drugs for inhibiting cholesterol synthesis, drugs for reducing fatty acid synthesis, drugs for preventing and / or treating diabetes, drugs for preventing and / or treating tumors, drugs for preventing and / or treating Parkinson's disease, drugs for preventing and / or treating Alzheimer's disease or drugs for prolonging the lifespan of organisms. The FBP aldolase is used as a target to develop theAMPK activating drugs. Difficulties existing in the prior art in direct using of AMPK as a drug target can be overcome, and the FBP aldolase has a good application prospect.

Description

technical field [0001] The invention belongs to the field of biomedicine, and relates to the application of FBP aldolase in the preparation of drugs for activating AMPK. The present invention also relates to the preparation of drugs for inhibiting cholesterol synthesis, drugs for reducing fatty acid synthesis, drugs for preventing and / or treating diabetes, drugs for preventing and / or treating tumors, drugs for preventing and / or treating Parkinson's disease, drugs for preventing and / or treating Or use in medicines for treating Alzheimer's disease or medicines for prolonging the lifespan of mammals. Background technique [0002] 5'-adenosine monophosphate-activated protein kinase (AMPK) is an important molecule that regulates the energy balance of cells and the body. AMPK consists of three different subunits, each of which has several isoforms: α subunit (α1 or α2); β subunit (β1 or β2); and γ subunit (γ1, γ2 or γ3 ); there are a total of 12 possible isoforms of heterotrimer...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K48/00A61K31/7105A61K39/395A61P3/06A61P3/04A61P3/10A61P35/00A61P25/16A61P25/28A61P39/06C12N15/867C12N5/10
CPCA61K31/7105A61K39/395A61K48/005C12N9/1007C12N15/86C12N2740/15043C12Y201/01259A61K48/00A61P3/04A61P3/06A61P3/10A61P5/50A61P25/16A61P25/28A61P35/00A61P39/06C12N5/10C12N9/88C12N15/867
Inventor 林圣彩张宸崧
Owner XIAMEN VIVOHEALTHS TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com